ArticleRenal failure2026
Activation of the TGF-β1/HIPK2 signaling pathway exacerbates EMT injury in renal tubular epithelial cells in diabetic kidney disease.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is a common and challenging microvascular complication of diabetes. TGF-β1-mediated epithelial-to-mesenchymal transition (EMT) in renal tubular epithelial cells, characterized by loss of epithelial polarity and intercellular adhesion alongside acquisition of a mesenchymal phenotype, is widely recognized as a key driver of DKD. Here, we reveal that renal interstitial fibrosis (RIF) and EMT constitute important pathological foundations for DKD progression, validated in both clinical DKD patients and DKD mouse models. Concurrently, we confirm the elevated expression of homoeotic domain-interacting protein kinase 2 (HIPK2) in DKD, though its regulatory role in EMT remains unclear. We further established a DKD-EMT cellular model by inducing human renal tubular epithelial cells (HK-2) with TGF-β1 combined with high glucose stimulation. Here, we found that inhibiting HIPK2 expression significantly delayed EMT progression and improved RIF in DKD. Thus, our study provides a novel therapeutic strategy for DKD progression and demonstrates that HIPK2 serves as a potential therapeutic target for DKD-EMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.